Company Valuation: Checkpoint Therapeutics, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Market Cap 1 88.79 179.9 260.5 52.39 53.87 156.3
Change - 102.61% 44.83% -79.89% 2.84% 190.05%
Enterprise Value (EV) 1 62.71 139.1 205.8 40.32 48.95 149.7
Change - 121.85% 47.93% -80.41% 21.4% 205.76%
P/E -2.46x -6.41x -4.64x -0.84x -1.23x -2.26x
PBR 4.93x 5.2x 8.84x -2.7x -4.87x -13.8x
PEG - 0.2x -0.1x 0.09x 0x 0.1x
Capitalization / Revenue 52x 168x 972x 273x 523x 3,811x
EV / Revenue 36.7x 130x 768x 210x 475x 3,650x
EV / EBITDA - - - - - -
EV / EBIT -2.52x -6x -3.63x -0.69x -0.94x -2.66x
EV / FCF -4.08x -10.3x -16.2x -1.49x -1.13x -8.05x
FCF Yield -24.5% -9.75% -6.18% -66.9% -88.4% -12.4%
Dividend per Share 2 - - - - - -
Rate of return - - - - - -
EPS 2 -7 -4.134 -6.701 -6.088 -1.869 -1.418
Distribution rate - - - - - -
Net sales 1 1.708 1.069 0.268 0.192 0.103 0.041
EBITDA - - - - - -
EBIT 1 -24.85 -23.2 -56.72 -58.33 -52.15 -56.17
Net income 1 -24.71 -23.08 -56.67 -62.62 -51.85 -56.24
Net Debt 1 -26.08 -40.77 -54.74 -12.07 -4.928 -6.604
Reference price 2 17.200 26.500 31.100 5.110 2.290 3.200
Nbr of stocks (in thousands) 5,162 6,788 8,377 10,252 23,526 48,833
Announcement Date 11/03/20 12/03/21 28/03/22 31/03/23 22/03/24 28/03/25
1USD in Million2USD
Estimates

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 357M
21.98x7.69x15.68x1.34% 73.25B
35.55x9.09x27.97x0.04% 61.95B
-81.11x15.16x-77.38x-.--% 28.02B
30.63x6x15.89x-.--% 24.15B
-14.36x4.96x-6.48x-.--% 23.01B
53.29x19.73x39.94x0.07% 18.35B
26.57x5.01x16.8x-.--% 19.46B
-664.91x38.2x-17593.58x-.--% 15.92B
16.23x4.79x11.18x-.--% 12.96B
Average -64.02x 12.29x -1,950.00x 0.16% 27.74B
Weighted average by Cap. -25.01x 10.61x -1,003.04x 0.37%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. CKPT Stock
  4. Valuation Checkpoint Therapeutics, Inc.